2) Miller WL, Fluck CE : Adrenal Cortex and its disorders. In : Pediatric Endocrinology, 4th ed, p471-532, Elsevier Saunders, Philadelphia, 2014.
日本臨牀 別冊 内分泌症候群（第3版）II
目次
- III 副腎
1. 副腎皮質機能低下症
2. Cushing症候群
3. アルドステロン異常症
4. 先天性副腎皮質過形成・副腎皮質酵素異常症
5. 副腎腫瘍による性徴異常症
6. 副腎皮質腫瘍
7. 副腎髄質疾患
8. その他
IV 副甲状腺・骨・ミネラル代謝
1．副甲状腺機能亢進症
2．副甲状腺機能低下症
3．代謝性骨疾患
4．カルシウム、マグネシウム代謝異常
5．その他
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
III 副腎
P.8 掲載の参考文献
P.13 掲載の参考文献
1) 柳瀬敏彦, ほか : アジソン病, 副腎性サブクリニカルクッシング症候群の全国における実態調査. 厚生労働科学研究費補助金難治性疾患克服研究事業, 平成22年度研究報告書, p139-146, 2011.
6) 岩間信太郎, 有馬寛 : 免疫チェックポイント阻害剤による内分泌副作用の臨床とそのメカニズム. 日本臨床免疫学会会誌 40 : 90-94, 2017.
7) 柳瀬敏彦, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl) : 1-78, 2015.
9) Kraan GP, et al : The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab 83 : 1247-1252, 1998.
P.17 掲載の参考文献
1) Clark AJ, Weber A : Adrenocorticotropin insensitivity syndromes. Endocr Rev 19 : 828-843, 1998.
5) Allgrove J, et al : Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1 : 1284-1286, 1978.
11) Sadeghi-Nejad A, Senior B : Adrenomyeloneuropathy presenting as Addison's disease in childhood. N Engl J Med 322 : 13-16, 1990.
P.22 掲載の参考文献
3) Kang Y, et al : CRISPR/Cas9-mediated Daxl knockout in the monkey recapitulates human AHC-HH. Hum Mol Genet 24 : 7255-7264, 2015.
4) Suntharalingham JP, et al : DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Pract Res Clin Endocrinol Metab 29 : 607-619, 2015.
9) Sadeghi-Nejad A, Senior B : Adrenomyeloneuropathy presenting as Addison's disease in childhood. N Engl J Med 322 : 13-16, 1990.
10) Frapsauce C, et al : Birth after TESE-ICSI in a man with hypogonadotropic hypogonadism and congenital adrenal hypoplasia linked to a DAX-1 (NR0B1) mutation. Hum Reprod 26 : 724-728, 2011.
P.26 掲載の参考文献
5) Puar TH, et al : Adrenal Crisis : Still a Deadly Event in the 21st Century. Am J Med 129 : 339. e1-9, 2016.
7) 柳瀬敏彦, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl) : 1-78, 2015.
8) Bouillon R : Acute adrenal insufficiency. Endocrinol Metab Clin North Am 35 : 767-775, ix, 2006.
9) Jung C, Inder WJ : Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust 188 : 409-413, 2008.
P.30 掲載の参考文献
4) Trence DL : Management of patients on chronic glucocorticoid therapy : an endocrine perspective. Prim Care 30 : 593-605, 2003.
6) Tamada D, et al : Hyperthyroidism due to thyroid-stimulating hormone secretion after surgery for Cushing's syndrome : a novel cause of the syndrome of inappropriate secretion of thyroid- stimulating hormone. J Clin Endocrinol Metab 98 : 2656-2662, 2013.
7) Farrell RJ, Kelleher D : Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178 : 339-346, 2003.
8) Maier A, et al : Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 150 : 361-368, 2007.
9) De Kloet ER : Why dexamethasone poorly penetrates in brain. Stress 2 : 13-20, 1997.
10) 日本内分泌学会, 日本小児内分泌学会, 日本ステロイドホルモン学会, 厚生労働科学研究費補助金政策研究事業「副腎ホルモン産生異常に関する調査研究」班合同作成 : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl Sep) : 1-78, 2015.
P.35 掲載の参考文献
4) 松澤幸正, ほか : 副腎出血～自験例6例と症例報告57例の検討～. 日本泌尿器科学会雑誌 106 : 95-102, 2015.
5) To'o KJ, et al : Imaging of traumatic adrenal injury. Emerg Radiol 19 : 499-503, 2012.
6) Margaretten W, et al : Septicemic adrenal hemorrhage. Am J Dis Child 105 : 346-351, 1963.
7) Marti JL, et al : Spontaneous adrenal hemorrhage with associated masses : etiology and management in 6 cases and a review of 133 reported cases. World J Surg 36 : 75-82, 2012.
12) 日本内分泌学会, 日本小児内分泌学会, 日本ステロイドホルモン学会, 厚生労働科学研究費補助金政策研究事業「副腎ホルモン産生異常に関する調査研究」班合同作成 : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 第4部 急性副腎不全症の治療. 日本内分泌学会雑誌 91 (Suppl Sep) : 74-76, 2015.
14) 日本内分泌学会 (編) : 第9章 副腎および関連疾患 12副腎クリーゼ. 内分泌代謝科専門医研修ガイドブック, p422-423, 診断と治療社, 2018.
15) Rao RH : Bilateral massive adrenal hemorrhage. Med Clin North Am 79 : 107-129, 1995.
16) Pode D, et al : Spontaneous retroperitoneal hemorrhage. J Urol 147 : 311-318, 1992.
P.40 掲載の参考文献
3) 藤枝憲二, ほか : 副腎ホルモン産生異常症の全国疫学調査. 厚生労働科学研究費補助金難治性. 疾患克服研究事業「副腎ホルモン産生異常に関する調査研究」, 平成22年度総括・分担研究報告書, p89-102, 2011.
10) Allgrove J, et al : Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1 : 1284-1286, 1978.
P.43 掲載の参考文献
1) Chrousos GP, et al : Primary cortisol resistance in man. A glucocorticoid receptor-mediated disease. J Clin Invest 69 : 1261-1269, 1982.
2) De Groot LJ, et al : Primary Generalized Glucocorticoid Resistance or Chrousos Syndrome-Endotext [Internet], MD Text, South Dartmouth, 2000.
4) Vingerhoeds AC, et al : Spontaneous hypercortisolism without Cushing's syndrome. J Clin Endocrinol Metab 43 : 1128-1133, 1976.
6) Ruiz M, et al : Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf) 55 : 363-371, 2001.
7) Karl M, et al : Cushing's disease preceded by generalized glucocorticoid resistance : clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation. Proc Assoc Am Physicians 108 : 296-307, 1996.
8) Kino T, et al : Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus : importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocrinol Metab 86 : 5600-5608, 2001.
12) Raef H, et al : Genotype-phenotype correlation in a family with primary cortisol resistance : possible modulating effect of the ER22/23EK polymorphism. Eur J Endocrinol 158 : 577-582, 2008.
13) Nader N, et al : A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain. J Clin Endocrinol Metab 95 : 2281-2285, 2010.
16) Vottero A, et al : A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with pl60 steroid receptor coactivators. J Clin Endocrinol Metab 87 : 2658-2667, 2002.
P.48 掲載の参考文献
1) Betterle C, et al : The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 117 : 467-475, 1988.
3) Laureti S, et al : Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab 83 : 3507-3511, 1998.
5) Laureti S, et al : Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in preclinical Addison's disease. Clin Endocrinol (Oxf) 53 : 107-115, 2000.
9) Yamamoto T : History of stress-related health changes : a cue to pursue a diagnosis of latent primary adrenal insufficiency. Intern Med 53 : 183-188, 2014.
10) Baker PR, et al : Predicting the onset of Addison's disease : ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clin Endocrinol (Oxf) 76 : 617-624, 2012.
11) Nishikawa T, et al : Clinicians sometimes miss cases of latent primary adrenal insufficiency involving stress-related health changes. Intern Med 53 : 169-170, 2014.
12) 柳瀬敏彦, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl) : 1-78, 2015.
P.52 掲載の参考文献
1) Haberfield W, Spieler F : Zur diffusen Hirn-Ruckenmarksklerose im Kindesalter. Dt Z Nervheilk 40 : 436-463, 1910.
5) Loes DJ, et al : Adrenoleukodystrophy : a scoring method for brain MR observations. AJNR Am J Neuroradiol 15 : 1761-1766, 1994.
8) 副腎白質ジストロフィー (ALD) 診療ガイドライン 2017 (副腎自質ジストロフィー (ALD) 診療ガイドライン作成委員会編), p2-19, 診断と治療社, 2017.
12) 厚生労働省難治性疾患等克服研究事業 先天代謝異常症に対する移植療法の確立とガイドラインの作成に関する研究班 (代表 : 加藤俊一), 平成24～25年度総合研究報告書, p131-139, 2014.
P.58 掲載の参考文献
2) 柳瀬敏彦 : アジソン病最新医学 71 : 1969-1976, 2016.
3) 柳瀬敏彦, ほか : アジソン病診断基準・副腎不全症 重症度分類. 副腎ホルモン産生異常に関する調査研究, 平成26年度総括・分担研究報告書, p38-39, 2015.
4) 柳瀬敏彦, ほか : アジソン病診療指針. 副腎ホルモン産生異常に関する調査研究, 平成27年度総括・分担研究報告書, p63-68. 2016.
5) 柳瀬敏彦, ほか : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl) : 1-78, 2015.
6) 柳瀬敏彦, ほか : 厚生労働科学研究費補助金難治性疾患克服研究事業, 平成22年度研究報告書, p139-146, 2011.
15) Bergthorsdottir R, et al : Premature mortality in patients with Addison's disease : apopulation-based study. J Clin Endocrinol Metab 91 : 4849-4853, 2006.
P.64 掲載の参考文献
3) Hughes IA, Chatterjee VK : Adrenarche and adrenopause. In : Endocrinology : Adult and Pediatric, 7th ed (ed by Jameson JL, et al.), p1833-1840. e3, Saunders, Elsevier, Philadelphia, 2016.
6) Hannah-Shmouni F, Stratakis CA : An overview of inborn errors of metabolism manifesting with primary adrenal insufficiency. Rev Endocr Metab Disord 2018 Jun 28. [Epub ahead of print]
10) Homma K, et al : Elevated urine pregnanetriolone definitively establishes the diagnosis of classical 21-hydroxylase deficiency in term and preterm neonates. J Clin Endocrinol Metab 89 : 6087-6091, 2004.
11) Koyama Y, et al : Two-step biochemical differential diagnosis of classic 21-hydroxylase deficiency and cytochrome P450 oxidoreductase deficiency in Japanese infants by GC-MS measurement of urinary pregnanetriolone/tetrahydroxycortisone ratio and 11β-hydroxyan-drosterone. Clin Chem 58 : 741-747, 2012.
P.70 掲載の参考文献
1) Lacroix A, et al : Cushing's syndrome. Lancet 386 : 913-927, 2015.
2) 名和田新 : 副腎ホルモン産生異常症の全国疫学調査 厚生省特定疾患「副腎ホルモン産生異常症」調査研究班, 平成10年度研究報告書, p1-55, 1999.
3) 田辺晶代, 成瀬光栄 : ACTH非依存性クッシング症候群 病態生理・診断. クッシング症候群診療マニュアル (改訂第2版), p158-160, 診断と治療社, 2015.
4) Ross EJ, Linch DC : Cushing's syndrome-killing disease : discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2 : 646-649, 1982.
6) Dekkers OM, et al : Multisystem morbidity and mortality in Cushing's syndrome : a cohort study. J Clin Endocrinol Metab 98 : 2277-2284, 2013.
P.75 掲載の参考文献
1) Brown WH : A case of pluriglandular syndrome : diabetes of bearded women. Lancet 2 : 1022-1023, 1928.
2) Meador CK, et al : Cause of Cushing's syndrome in patients with tumors arising from "nonendocrine" tissue. J Clin Endocrinol Metab 22 : 693-703, 1962.
4) Pearse AG, Polak JM : Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut 12 : 783-788, 1971.
7) Isidori AM, Lenzi A : Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol 51 : 1217-1225, 2007.
10) Ilias I, et al : Cushing's syndrome due to ectopic corticotropin secretion : twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 90 : 4955-4962, 2005.
11) Invitti C, et al : Diagnosis and management of Cushing's syndrome : results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 84 : 440-448, 1999.
12) Newell-Price J : The desmopressin test and Cushing's syndrome : current state of play. Clin Endocrinol (Oxf) 47 : 173-174, 1997.
14) Lacroix A, et al : Cushing's syndrome. Lancet 386 : 913-927, 2015.
15) Boscaro M, Arnaldi G : Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab 94 : 3121-3131, 2009.
16) Isidori AM, et al : Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome : A Systematic Review. J Clin Endocrinol Metab 100 : 3231-3244, 2015.
17) Davi' MV, et al : Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors : a multicenter study. Eur J Endocrinol 176 : 451-459, 2017.
18) Nagy-Mignotte H, et al : Prognostic impact of paraneoplastic cushing's syndrome in small-cell lung cancer. J Thorac Oncol 9 : 497-505, 2014.
P.80 掲載の参考文献
1) Bailey RE : Periodic hormonogenesisd-a new phenomenon. Periodicity in function of a hormone-producing tumor in man. J Clin Endocrinol Metab 32 : 317-327, 1971,
2) Brown RD, et al : Cushing's disease with periodic hormonogenesis : one explanation for paradoxical response to dexamethasone. J Clin Endocrinol Metab 36 : 445-451, 1973.
3) Green JR, van't Hoff W : Cushing's syndrome with fluctuation due to adrenal adenoma. J Clin Endocrinol Metab 41 : 235-240.
4) Adachi M, et al : Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine. Intern Med 35 : 207-211, 1996.
5) Meinardi JR, et al : Cyclic Cushing's syndrome : a clinical challenge. Eur J Endocrinol 157 : 245-254, 2007.
7) Mercado-Asis LB, et al : Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine. Endocrinol Jpn 38 : 315-324, 1991.
8) Jordan RM, et al : Dynamics of adrenocorticotropin (ACTH) secretion in cyclic Cushing's syndrome : evidence for more than one abnormal ACTH biorhythm. J Clin Endocrinol Metab 55 : 531-537, 1982.
9) Beckers A, et al : Cyclical Cushing's disease and its successful control under sodium valproate. J Endocrinol Invest 13 : 923-929, 1990.
10) Yamagami K, et al : Pituitary cyclic Cushing's syndrome concomitant with solitary cryptococcal pneumonia confused with ectopic ACTH-producing tumor. Intern Med 51 : 1055-1060, 2012.
11) Arnaldi G, et al : Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors. J Clin Endocrinol Metab 88 : 5834-5840, 2003.
12) Yasuda K : Cyclic Cushing's disease : Pitfalls in the Diagnosis and Problems with the Pathogenesis. Intern Med 35 : 169-170, 1996.
13) Manenschijn L, et al : A novel tool in the diagnosis and follow-up of (cyclic) Cushing's syndrome : measurement of long-term cortisol in scalp hair. J Clin Endocrinol Metab 97 : 1836-1843, 2012.
14) Asano S, et al : Long-term remission of cyclic Cushing's disease that was diagnosed and treated surgically in non-active phase. Endocr J 54 : 407-412, 2007.
P.84 掲載の参考文献
1) 柳瀬敏彦, ほか : アジソン病, 副腎性サブクリニカルクッシング症候群の全国における実態調査 厚生労働科学研究費補助金難治性疾患克服研究事業, 平成22年度研究報告書, p117-124, 2011.
8) 名和田新 : 厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査分科会, 平成7年度研究報告書, p223-226, 1996.
9) 日本内分泌学会, ほか : 日本内分泌学会臨床重要課題 潜在性クッシング症候群 (下垂体性と副腎) の診断基準の作成「副腎性サブクリニカルクッシング症候群 新診断基準」の作成と解説. 日本内分泌学会雑誌 93 (Suppl) : 1-18, 2017.
10) 名和田新, ほか : 副腎ホルモン産生異常症の全国疫学調査. 厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査分科会, 平成10年度研究報告書, p11-55, 1999.
12) Assie G, et al : ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 369 : 2105-2114, 2013.
13) Shen J, et al : Nonconformity in the clinical practice guidelines for subclinical Cushing's syndrome : which guidelines are trustworthy? Eur J Endocrinol 171 : 421-431, 2014.
14) Akehi Y, et al : Proposed diagnostic criteria for subclinical Cushing's syndrome associated with adrenal incidentaloma. Endocr J 60 : 903-912, 2013.
15) Chiodini I, et al : Six controversial issues on subclinical Cushing's syndrome. Endocrine 56 : 262-266, 2017.
16) 一城貴政, ほか : 本邦における5年間の継続的副腎偶発腫疫学調査-最終報告-厚生労働省研究補助金難治性疾患克服研究事業 副腎ホルモン産生異常に関する調査研究, 平成16年度研究報告書, p121-129, 2005.
P.89 掲載の参考文献
1) Alwani RA, et al : Differentiating between Cushing's disease and pseudo-Cushing's syndrome : comparison of four tests. Eur J Endocrinol 170 : 477-486, 2014.
2) Nieman LK : Cushing's syndrome : update on signs, symptoms and biochemical screening. Eur J Endocrinol 173 : M33-38, 2015.
3) Findling JW, Raff H : DIAGNOSIS OF ENDOCRINE DISEASE : Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome). Eur J Endocrinol 176 : R205-R216, 2017.
4) Newell-Price J, et al : The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19 : 647-672, 1998.
6) Drougat L, et al : Genetics of primary bilateral macronodular adrenal hyperplasia : a model for early diagnosis of Cushing's syndrome? Eur J Endocrinol 173 : M121-131, 2015.
8) Yanovski JA, et al : Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269 : 2232-2238, 1993.
9) Tamada D, et al : Obstructive sleep apnea syndrome causes a pseudo-Cushing's state in Japanese obese patients with type 2 diabetes mellitus. Endocr J 60 : 1289-1294, 2013.
10) Tamada D, et al : TSH ratio as a novel diagnostic method for Cushing's syndrome. Endocr J 65 : 841-848, 2018.
P.92 掲載の参考文献
2) Kiefer FW, et al : PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. Eur J Endocrinol 177 : K7-K12, 2017.
4) PRKAR1A Mutation Database. [https://prkarla.nichd.nih.gov/hmdb/prkarla.html]
6) Korpaisarn S, et al : A Novel PRKAR1A Mutation Identified in a Patient with Isolated Primary Pigmented Nodular Adrenocortical Disease. Case Rep Oncol 10 : 769-776, 2017.
8) Rothenbuhler A, et al : Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf) 77 : 195-199, 2012.
12) Cignarelli M, et al : A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex. J Endocrinol Invest 28 : 54-60, 2005.
14) Kaltsas G, et al : Carney Complex. Endotext [Internet], June 18, 2018.
P.98 掲載の参考文献
1) Assie G, et al : ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med 369 : 2105-2114, 2013.
4) Drougat L, et al : Genetics of primary bilateral macronodular adrenal hyperplasia : a model for early diagnosis of Cushing's syndrome? Eur J Endocrinol 173 : M121-131, 2015.
6) Espiard S, et al : ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia : Clinical and Functional Consequences. J Clin Endocrinol Metab loo : E926-935, 2015.
7) Elbelt U, et al : Molecular and clinical evidence for an ARMC5 tumor syndrome : concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma. J Clin Endocrinol Metab loo : E119-128, 2015.
P.103 掲載の参考文献
1) Conn JW : Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955.
3) Opocher G, et al : Differential diagnosis in primary aldosteronism. J Steroid Biochem Mol Biol 45 : 49-55, 1993.
5) 西川哲男, ほか : 原発性アルドステロン症の診断治療ガイドライン-2009-. 日本内分泌学会雑誌 86 (Suppl) : 1-19, 2010.
6) Williams TA, et al : Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018. [Epub ahead of print]
7) Williams TA, et al : Outcomes after adrenalectomy for unilateral primary aldosteronism : an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 5 : 689-699, 2017.
8) Makita K, et al : A Novel Method : Super-selective Adrenal Venous Sampling. J Vis Exp 127 : 55716, 2017.
P.107 掲載の参考文献
2) Schirpenbach C, Reincke M : Primary aldosteronism : current knowledge and controversies in Conn's syndrome. Nat Clin Pract Endocrinol Metab 3 : 220-227, 2007.
4) Beuschlein F, et al : Somatic mutations in ATP1AI and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 45 : 440-444, 444e1-2, 2013.
5) 中村保宏, ほか : 原発性アルドステロン症の病理. 日本内分泌・甲状腺外科学会雑誌 30 : 32-35, 2013.
6) 中村保宏, ほか : 原発性アルドステロン症の病理組織診断 : update 2017. 日本内分泌・甲状腺外科学会雑誌 35 : 8-12, 2018.
9) 西川哲男, ほか : 原発性アルドステロン症の診断治療ガイドライン-2009-. 日本内分泌学会雑誌 86 : 1-19, 2010.
10) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 二次性高血圧. 高血圧治療ガイドライン 2014, p115-130, ライフサイエンス出版, 2014.
11) 日本内分泌学会, 日本内分泌学会誌 (編) : 日本内分泌学会臨床重要課題「わが国の原発性アルドステロン症の診療に関するコンセンサス・ステートメント」日本内分泌学会雑誌 92 (Suppl) : 1-47, 2016.
12) Nishikawa T, et al : Is it possible to extirpate cardiovascular events in primary aldosteronism after surgical treatment. Jpn Clin Med 1 : 21-23, 2010.
13) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
14) Pitt B, et al : The EPHESUS trial : eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15 : 79-87, 2001.
P.110 掲載の参考文献
1) Sutherland DJA, et al : Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95 : 1109-1119, 1966.
3) 上牧務, ほか : キメラ遺伝子が証明されたグルココルチコイド反応性アルドステロン症の母子例. 日本先天代謝異常学会雑誌 11 : 110, 1995.
4) Yokota K, et al : Japanese family with glucocorticoid-remediable aldosteronism diagnosed by long-polymerase chain reaction. Hypertens Res 24 : 589-594, 2001.
6) Litchfield WR, et al : Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82 : 3570-3573, 1997.
7) Mulatero P, et al : Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism : aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 83 : 2573-2575, 1998.
P.112 掲載の参考文献
2) Omura M, et al : Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metab Clin Exp 51 : 350-355, 2002.
3) Makita K, et al : A novel method : Super-selective adrenal venous sampling. J Vis Exp (127), 2017. (doi : 10.3791/55716)
8) 日本内分泌学会 原発性アルドステロン症検討委員会 : 日本内分泌学会臨床重要課題-原発性アルドステロン症の診断治療ガイドライン-2009-. 日本内分泌学会雑誌 86 (Suppl 2) : 1-19, 2010.
P.116 掲載の参考文献
1) Fraser R, et al : Clinical and biochemical studies of a patient with a corticosterone-secreting adrenocortical tumour. Lancet 2 : 1116-1120, 1968.
2) Edwards OM, et al : Proceedings : Steroid production rates in two patients with corticosterone-producing adenomata. J Endocrinol 65 : 52P-53P, 1975.
3) Tait AD, et al : Proceedings : Evidence for a non-cholesterol pathway in steroidogenesis in two human corticosterone-secreting adrenal adenomata. J Endocrinol 65 : 53P-54P, 1975.
4) Krolner B, et al : Corticosterone secreting adrenal carcinoma and empty sella turcica : a case report. Acta Endocrinol 91 : 650-656, 1979.
5) Mills IH, et al : Corticosterone-secreting tumours : with and without renal artery stenosis. Clin Endocrinol (Oxf) 13 : 355-360, 1980.
6) 北川元昭, ほか : コルチコステロン産生副腎皮質腫瘍の1例. 日本泌尿器科学会雑誌 79 : 1712-1717, 1988.
8) Makino K, et al : An adrenocortical tumor secreting weak mineralocorticoids. Endocrinol Jpn 34 : 65-72, 1987.
9) Morioka M, et al : Adrenal adenoma with excess secretion of corticosterone and 18-hydroxycorticosterone. J Urol 144 : 731-732, 1990.
10) Nitta T, et al : Bilateral deoxycorticosterone-secreting adrenocortical adenoma. Int J Urol 3 : 494-496, 1996.
11) Wada S, et al : Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. Intern Med 41 : 304-308, 2002.
12) 吉川和朗, ほか : Preclinical Cushing症候群を合併したコルチコステロン産生副腎腫瘍の1例. 泌尿器外科 20 : 312, 2007.
13) 澤村俊孝 : 肝・肺・脾の多発転移巣に対しミトタンが著効した11-DOC, コルチコステロン産生副腎癌の一例. 日本内分泌学会雑誌 88 : 379, 2012.
14) Shibata H, et al : Significance of steroidogenic enzymes in the pathogenesis of adrenal tumour. Acta Endocrinol 128 : 235-242, 1993.
P.120 掲載の参考文献
1) Shibata H, et al : Significance of steroidogenic enzymes in the pathogenesis of adrenal tumour. Acta Endocrinol 128 : 235-242, 1993.
2) Shibata H, et al : Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors : possible implications in steroidogenesis. Mol Genet Metab 74 : 206-216, 2001.
3) White WB, et al : Diurnal blood pressure variability in mineralocorticoid excess syndrome. Am J Hypertens 5 : 414-418, 1992.
4) Komura T, et al : [A case of deoxycorticosterone-producing adrenal tumor]. Hinyokika Kiyo 39 : 145-149, 1993.
5) Furuse H, et al : [Deoxycorticosterone-producing adrenocortical carcinoma-a case report]. Nihon Hinyokika Gakkai Zasshi 86 : 957-960, 1995.
7) Wada N, et al : A case of deoxycorticosterone-producing adrenal adenoma. Endocr J 42 : 637-642, 1995.
8) Toyoda Y, et al : Adrenal tumor producing 11-deoxycorticosterone, 18-hydroxy-11-deoxycorticosterone and aldosterone. Intern Med 35 : 123-128, 1996.
9) Nitta T, et al : Bilateral deoxycorticosterone-secreting adrenocortical adenoma. Int J Urol 3 : 494-496, 1996.
11) Soranno D, et al : Hypertension and virilization caused by a unique desoxycorticosterone- and androgen-secreting adrenal adenoma. J Pediatr Endocrinol Metab 12 : 215-220, 1999.
12) Takahashi Y, et al : Primary amenorrhea accompanied by adrenal adenoma : start of menarche soon after tumor resection. Intern Med 41 : 972-976, 2002.
13) Mussig K, et al : Adrenocortical carcinoma producing 11-deoxycorticosterone : a rare cause of mineralocorticoid hypertension. J Endocrinol Invest 28 : 61-65, 2005.
14) Sone M, et al : Close examination of steroidogenesis disorders in a DOC-and progesterone-producing adrenocortical carcinoma. Endocrine 35 : 25-33, 2009.
P.124 掲載の参考文献
3) Revers FE : Heeft succus liquiritiae een genezende werking op de maagzweer? Ned Tijdschr Geneeskd 90 : 135-137, 1946.
6) Stewart PM, et al : Mineralocorticoid activity of iiquorice : 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2 : 821-824, 1987.
9) Makino T, et al : Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver inj ury. Drug Metab Dispos 36 : 1438-1443, 2008.
10) Makino T, et al : 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2. J Pharmacol Exp Ther 342 : 297-304, 2012.
11) 森本靖彦, 中島智子 : 甘草製剤による偽アルドステロン症のわが国における現状. 和漢医薬学会誌 8 : 1-22, 1991.
12) 柴田洋孝, 伊藤裕 : 偽アルドステロン症の重症副作用への疾患別対応. 日本内科学会雑誌 96 : 805-810, 2007.
14) 新井桂子, ほか : 低カルシウム血症を伴ったグリチルリチンによる偽性アルドステロン症の1例. 内科 68 : 593-595, 1991.
15) 厚生労働省 : 偽アルドステロン症. 重篤副作用疾患別対応マニュアル (平成18年11月版), 2006.
P.130 掲載の参考文献
2) Agarwal AK, et al : Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem 264 : 18939-18943, 1989.
3) Tannin GM, et al : The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266 : 16653-16658, 1991.
6) Odermatt A, et al : The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274 : 28762-28770, 1999.
7) Taylor NF, et al : Cortisone reductase deficiency : evidence for a new inborn error in metabolism of adrenal steroids. J Endocrinol (Oxf) 102 (Suppl) : 90 (Abstract), 1984.
P.135 掲載の参考文献
1) Werder EA, et al : Unusual steroid excretion in a child with low-renin hypertension. Res Steroids 6 : 385-389, 1974.
4) Agarwal AK, et al : NAD+ -dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J Biol Chem 269 : 25959-25962, 1994.
6) White PC, et al : 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 : 135-156, 1997.
7) Mune T, White PC : Apparent mineralocorticoid excess : genotype is correlated with biochemical phenotype. Hypertension 27 : 1193-1199, 1996.
10) 村松学, ほか : Apparent Mineralocorticoid Excess (AME) 症候群. 日本臨牀 63 (増刊号 : 臨床分子内分泌学 (2)) : 302-308, 2005.
12) Yau M, et al : Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency. Proc Natl Acad Sci USA 114 : E11248-E11256, 2017.
15) 宗友厚 : 遺伝性副腎疾患の現状 Apparent Mineralocorticoid Excess症候群. ホルモンと臨床 60 : 183-187, 2012.
P.140 掲載の参考文献
1) 向山政志, 中尾一和 : 選択的低アルドステロン症 [高レニン・低レニン性]. 別冊日本臨床 新領域別症候群シリーズ 内分泌症候群 (第2版) I, p655-660, 日本臨牀社, 2006.
2) 福地総逸 : 選択的低アルドステロン症の臨床. 日本内分泌学会雑誌 73 : 423-429, 1997.
6) Sousa AG, et al : Hyporeninemic hypoaldosteronism and diabetes mellitus : pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes 7 : 101-111, 2016.
7) Yorke E, et al : Aldosterone deficiency after unilateral adrenalectomy for Conn's syndrome : a case report and literature review. Int J Surg Case Rep 7C : 141-144, 2015.
8) Inada M, et al : Hyperpotassemia and bradycardia in a bedridden elderly woman with selective hypoaldosteronism associated with low renin activity. Intern Med 49 : 307-313, 2010.
P.144 掲載の参考文献
3) Takeda Y, et al : Effect of adrenocorticotropin stimulation on the synthesis of 19-noraldosterone in man. J Clin Endocrinol Metab 81 : 1852-1855, 1996.
4) Zipser RD, et al : Hyperreninemic hypoaldosteronism in the critically ill : anew entity. J Clin Endocrinol Metab 53 : 867-873, 1981.
5) Takeda Y, et al : Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II. J Am Heart Assoc 7. pii : e008281, 2018.
6) Clark BA, et al : Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion : potential relevance to hypoaldosteronism in man. J Clin Endocrinol Metab 75 : 399-403, 1992.
7) du Cheyron D, et al : Hyperreninemic hypoaldosteronism : apossible etiological factor of septic shock-induced acute renal failure. Intensive Care Med 29 : 1703-1709, 2003.
9) Heering PJ, et al : Decreased mineralocorticoid receptor expression in blood cells of kidney transplant recipients undergoing immunosuppressive treatment : cost efficient determination by quantitative PCR. J Clin Pathol 57 : 33-36, 2004.
10) Takeda Y, et al : Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105 : 677-679, 2002.
11) 武田仁勇 : 選択的低アルドステロン症. 示説副腎皮質内分泌学 (竹田亮祐, 宮森勇編), p99-113, 文光堂, 1993.
12) Morimoto S, et al : Selective hypoaldosteronism with hyperreninemia in a diabetic patient. J Clin Endocrinol Metab 49 : 742-747, 1979.
P.148 掲載の参考文献
2) Dirlewanger M, et al : A homozygous missense mutation in SCNN1A is responsible for a transient neonatal form of pseudohypoaldosteronism type 1. Am J physiol Endocrinol Metab 301 : E467-473, 2011.
3) Hubert EL, et al : Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol 22 : 1997-2003, 2011.
13) Bowden SA, et al : Autosomal dominant pseudohypoaldosteronism type 1 in an infant with Salt wasting crisis associated with urinary tract infection and obstructive uropathy. Case Rep Endocrinol 2013 : 524647, 2013.
P.152 掲載の参考文献
1) Gordon RD, et al : Hypertension and severe hyperkalaemia associated with suppression of renin and aldos terone and completely reversed by dietary sodium restriction. Australas Ann Med 19 : 287-294, 1970.
3) Disse-Nicodeme S, et al : Familial hyperkalemic hypertension (Gordon syndrome) : evidence for phenotypic variability in a study of 7 families. Adv Nephrol Necker Hosp 31 : 55-68, 2001.
P.157 掲載の参考文献
6) Schmidt K, et al : Cholesterol metabolism : the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb. Mol Cell Biol 29 : 2716-2729, 2009.
8) 石津桂, ほか : 新生児マス・スクリーニング検査で発見され経過中に卵巣嚢胞茎捻転を起こしたP450オキシドレダクターゼ欠損の1例. 日本マス・スクリーニング学会誌 21 : 243-246, 2011.
P.162 掲載の参考文献
2) Wilson JD : Williams Textbook of Endocrinology, 13th ed, WB Saunders, Philadelphia, 2015.
3) Baumgartner-Parzer SM, et al : Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 90 : 775-778, 2005.
P.164 掲載の参考文献
1) Wilson JD : Williams Textbook of Endocrinology, 13th ed, WB Saunders, Philadelphia, 2015.
2) Hannah-Shmouni F, et al : Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med 19 : 1276-1279, 2017.
3) Wischusen J, et al : Reversible male infertility due to congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 14 : 571-577, 1981.
4) Falharnmar H, Torpy DJ : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as adrenal incidentaloma : A systematic review and meta-analysis. Endocr Pract 22 : 736-752, 2016.
P.168 掲載の参考文献
2) 日本小児内分泌学会 : 3β-ヒドロキシステロイド脱水素酵素欠損症「診断の手引き」小児慢性特定疾病情報センター, 2014. [http://www.shouman.jp] [2018年10月閲覧]
3) Luu The V, et al : Full length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol 3 : 1310-1312, 1989.
4) Miller WL, Fluck CE : 3β-hydroxysteroid dehydrogenase deficiency, Adrenal cortex and its disorders. In : Pediatric Endocrinology, 4th ed (ed by Sperling MA), p495-496, Saunders, Philadelphia, 2014.
5) Pang S, et al : A novel nonstop mutation in the stop codon and a novel missense mutation in the type II 3beta-hydroxysteroid dehydrogenase (3beta-HSD) gene causing, respectively, nonclassic and classic 3beta-HSD deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 87 : 2556-2563, 2002.
6) Burckhardt MA, et al : Human 3β-hydroxysteroid dehydrogenase deficiency seems to affect fertility but may not harbor a tumor risk : lesson from an experiment of nature. Eur J Endocrinol 173 : K1-K12, 2015.
7) Achermann JC, Hughes IA : 3β-hydroxysteroid dehydrogenase/Δ4, 5-isomerase type 2 deficiency, Pediatric disorders of sex development. In : Williams Textbook of Endocrinology, 13th ed (ed by Melmed S, et al), p925-926, Elsevier, Philadelphia, 2016.
10) 石井智弘 : 3β水酸化ステロイド脱水素酵素欠損症. 小児内分泌学 [第2版] (日本小児内分泌学会編), p387-390, 診断と治療社, 2016.
11) 日本小児内分泌学会マス・スクリーニング委員会, 日本マス・スクリーニング学会 : 21-水酸化酵素欠損症の診断・治療のガイドライン (2014年改訂版), 2014. [http://jspe.umin.jp/medical/files/guide20140513.pdf]
12) Yoshimoto M, et al : Pubertal changes in testicular 3beta-hydroxysteroid dehydrogenase activity in a male with classical 3beta-hydroxysteroid dehydrogenase deficiency showing spontaneous secondary sexual maturation. Horm Res 48 : 83-87, 1997.
13) Rheaume E, et al : Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nat Genet 1 : 239-245, 1992. [2018年10月閲覧]
P.173 掲載の参考文献
1) Yanase T, et al : 17α-hydroxylase/17,20-lyase deficiency : from clinical investigation to molecular definition. Endocr Rev 12 : 91-108, 1991.
3) 柳瀬敏彦 : ステロイド産生酵素異常と不妊. Annual Review糖尿病・代謝・内分泌 2007, p241-247, 中外医学社, 2007.
4) Yanase T, et al : Deletion of a phenylalanine in the N-terminal region of human cytochrome P-450 (17 alpha) results in partial combined 17 alpha-hydroxylase/17,20-lyase deficiency. J Biol Chem 264 : 18076-18082, 1989.
5) Miura K, et al : Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism : with a review of Japanese patients with mutations of CYP17. J Clin Endocrinol Metab 81 : 3797-3801, 1996.
6) Taniyama M, et al : Subtle 17α-hydroxylase/17,20-lyase deficiency with homozygous Y201N mutation in an infertile women. J Clin Endocrinol Metab 90 : 2508-2511, 2005.
7) 柳瀬敏彦, ほか : 特集 内分泌性高血圧のスクリーニング指針 原発性アルドステロン症以外の鉱質コルチコイド受容体活性化病態. 血圧 25 : 240-245, 2018.
8) Yanase T, et al : Molecular basis of apparent isolated 17,20 lyase deficiency : compound heterozygous mutations in the C-terminal region (Arg (496) →Cys, Gln (461) →Stop) actually cause combined l7α-hydroxylase/17,20 lyase deficiency. Biochim Biophys Acta 1139 : 275-279, 1992.
10) Van Den Akker EL, et al : Differential inhibition of 17α-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab 87 : 5714-5721, 2002.
P.178 掲載の参考文献
2) Fujieda K, et al : Molecular pathogenesis of lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J Steroid Biochem Mol Biol 85 : 483-489, 2003.
5) Nakae J, et al : Analysis of the steroidogenic acute regulatory protein (StAR) gene in Japanese patients with congenital lipoid adrenal hyperplasia. Hum Mol Genet 6 : 571-576, 1997.
6) Kim CJ : Congenital lipoid adrenal hyperplasia. Ann Pediatr Endocrinol Metab 19 : 179-183, 2014.
7) Fujieda K, et al : Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. Ovarian steroidogenesis is spared to some extent despite inactivating mutations in the steroidogenic acute regulatory protein (StAR) gene. J Clin Invest 99 : 1265-1271, 1997.
8) Baker BY, et al : Nonclassic congenital lipoid adrenal hyperplasia : anew disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab 91 : 4781-4785, 2006.
10) Sahakitrungruang T, et al : Clinical, genetic, and functional characterization of four patients carrying partial loss-of-function mutations in the steroidogenic acute regulatory protein (StAR). J Clin Endocrinol Metab 95 : 3352-3359, 2010.
11) Khoury K, et al : Gonadal function, first cases of pregnancy, and child delivery in a woman with lipoid congenital adrenal hyperplasia. J Clin Endocrinol Metab 94 : 1333-1337, 2009.
12) Sertedaki A, et al : Conception and pregnancy outcome in a patient with 11-bp deletion of the steroidogenic acute regulatory protein gene. Fertil Steril 91 : 934. e15-18, 2009.
P.181 掲載の参考文献
1) Fujieda K, et al : Molecular pathogenesisof lipoid adrenal hyperplasia and adrenal hypoplasia congenita. J Steroid Biochem Mol Biol 85 : 483-489, 2003.
3) Tajima T, et al : Heterozygous mutation in the cholesterol side chain cleavage enzyme (p450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 86 : 3820-3825, 2001.
8) Rubtsov P, et al : A novel homozygous mutation in CYP11A1 gene is associated with late-onset adrenal insufficiency and hypospadias in a 46,XY patient. J Clin Endocrinol Metab 94 : 936-939, 2009.
11) Parajes S, et al : Delayed diagnosis of adrenal insufficiency in a patient with severe penoscrotal hypospadias due to two novel P450 side-change cleavage enzyme (CYP11A1) mutations (p. R360W ; p. R405X). Eur J Endocrinol 167 : 881-885, 2012.
P.186 掲載の参考文献
1) Bulsari K, Falhammar H : Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine 55 : 19-36, 2017.
2) White PC : Steroid 11β-hydroxylase deficiency and related disorders. In : Genetic Steroid Disorders (ed by New MI, et al), p71-85, Academic Press, San Diego, 2014.
4) 藤枝憲二, ほか : 副腎ホルモン産生異常症の全国疫学調査. 厚生労働科学研究費補助金難治性疾患克服研究事業 副腎ホルモン産生異常に関する調査研究班, 平成20-22年度総合研究報告書, p113-157, 2010.
7) Khattab A, et al : Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Proc Natl Acad Sci USA 114 : E1933-E1940, 2017.
8) Bas F, et al : Prevalence, clinical characteristics and long-term outcomes of classical 11β-hydroxylase deficiency (11BOHD) in Turkish population and novel mutations in CYP11B1 gene. J Steroid Biochem Mol Biol 181 : 88-97, 2018.
9) Azziz R, et al : 11 beta-hydroxylase deficiency in hyperandrogenism. Fertil Steril 55 : 733-741, 1991.
P.189 掲載の参考文献
1) Kondo E, et al : Two novel mutations of the CYP11B2 gene in a Japanese patient with aldosterone deficiency type L Endocr J 60 : 51-55. 2013.
2) Pascoe L, et al : Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 89 : 4996-5000, 1992.
3) Arai K, Chrousos GP : Aldosterone Deficiency and Resistance. In : Endotext [Internet] (ed by DeGroot LJ, et al), MDText. Com, Inc, South Dartmouth, 2000-, Last Update 2016 May 11.
4) Zhang G, et al : Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency. Am J Hum Genet 57 : 1037-1043, 1995.
5) Kayes-Wandover KM, et al : Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 86 : 5379-5382, 2001.
7) 唐島成宙, ほか : ステロイドの測定. 臨床泌尿器科 72 : 452-457, 2018.
8) Stapenhorst L : 9α-Fluorohydrocortisone therapy in aldosterone synthase deficiency. Pediatr Nephrol 20 : 839, 2005.
P.193 掲載の参考文献
1) 名和田新, 井林博 : Adrenogenital syndrome. 内科 53 : 1349-1353, 1984.
2) 島崎淳, ほか : 副腎癌. 日本臨牀 51 (増刊号 : 本邦臨床統計集-下巻) : 766-782, 1993.
3) 仲川嘉紀, ほか : 小児男性化副腎皮質腫瘍の1例. 泌尿器科紀要 35 : 1731-1736, 1989.
4) 櫻井晃洋 : MEN以外の遺伝性副腎皮質腫瘍. 日本内分泌・甲状腺外科学会雑誌 32 : 184-188, 2015.
5) Pang S, et al : Adrenocortical tumor in a patient with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 68 : 242-246, 1981.
6) van Seters AP, et al : Adrenocortical tumour in untreated congenital adrenocortical hyperplasia associated with inadequate ACTH suppressibility. Clin Endocrinol (Oxf) 14 : 325-334, 1981.
P.196 掲載の参考文献
1) 島崎淳, ほか : 副腎癌. 日本臨牀 51 (増刊号 : 本邦臨床統計集-下巻) : 766-782, 1993.
2) 櫻井晃洋 : MEN以外の遺伝性副腎皮質腫瘍. 日本内分泌・甲状腺外科学会雑誌 32 : 184-188, 2015.
3) Young J, et al : Aromatase expression in a feminizing adrenocortical tumor. J Clin Endocrinol Metab 81 : 3173-3176, 1996.
4) Phornphutkul C, et al : Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty. J Clin Endocrinol Metab 86 : 649-652, 2001.
P.204 掲載の参考文献
1) 一城貴政, ほか : 厚生労働省科学研究費補助金難治性疾患克服研究事業 副腎ホルモン産生異常に関する調査研究班, 平成16年度研究報告書, p121-129, 2005.
6) Ueland GA, et al : Adrenal venous sampling for assessment of autonomous cortisol secretion. J Clin Endocrinol Metab, 2018. [Epub ahead of print]
P.209 掲載の参考文献
1) 一城貴政, ほか : 厚生労働科学研究費補助金難治性疾患克服研究事業「副腎ホルモン産生異常に関する調査研究」班分担研究報告書副腎偶発腫長期予後調査最終報告-平成26年度報告, p51-59, 2015.
2) Fassnacht M, et al : Management of adrenal incidentalomas : European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 175 : G1-G34, 2016.
3) 日本内分泌学会, 日本ステロイドホルモン学会, 厚生労働科学研究費補助金政策研究事業「副腎ホルモン産生異常に関する調査研究」班 : 副腎性サブクリニカルクッシング症候群新診断基準. 日本内分泌学会雑誌 93 (Suppl Sep) : 1-18, 2017.
8) 神山隆治, 平田結喜緒 : 内分泌画像検査・診断マニュアル, p159-169, 診断と治療社, 2011.
9) Tenenbaum F, et al : 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in l3 consecutive patients. Eur J Endocrinol 150 : 789-792, 2004.
11) 柴田洋孝 : 副腎偶発腫瘍. 内科学書 [改訂第8版] (小川聡総編集), p174-176, 中山書店, 2013.
12) Young WF : Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356 : 601-610, 2007,
13) Cawood TJ, et al : Recommended evaluation of adrenal incidentalomas is costly, has high falsepositive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant ; time for a rethink? Eur J Endocrinol 161 : 513-527, 2009.
15) Zeiger MA, et al : The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 15 (Suppl 1) : 1-20, 2009.
P.214 掲載の参考文献
1) Sasano H, et al : Adrenal rest tumor of the broad ligament : case report with immunohistochemical study of steroidogenic enzymes. Pathol Int 47 : 493-496, 1997.
2) Falls JL : Accessory adrenal cortex in the broad ligament : incidence and functional significance. Cancer 8 : 143-150, 1955.
6) Yokoyama H, et al : Non-functioning adrenocortical carcinoma arising in an adrenal rest : immunohistochemical study of an adult patient. Tohoku J Exp Med 229 : 267-270, 2013.
8) Weiss LM : Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8 : 163-169, 1984.
10) Lin BT, et al : Oncocytic adrenocortical neoplasms : a report of seven cases and review of the literature. Am J Surg Pathol 22 : 603-614, 1998.
P.219 掲載の参考文献
1) Cohn K, et al : Adrenocortical carcinoma. Surgery 100 : 1170-1177, 1986.
2) Li FP, Fraumeni JF : Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71 : 747-752, 1969.
3) Lloyd R, et al (ed) : WHO Classification of Tumours of Endocrine Organs, 4th ed, IARC Press, Lyon, 2017.
4) Sasano H : Adrenal Cortex. In : Molecular and Cellular Endocrine Pathology, p221-252, Chapman and Hall Publishing Company, London, 1999.
6) Weiss LM : Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8 : 163-169, 1984.
8) van Slooten H, et al : Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55 : 766-773, 1985.
11) Fassnacht M, et al : Adrenocortical carcinoma : a clinician's update. Nat Rev Endocrinol 7 : 323-335, 2011.
13) Morimoto R, et al : Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas : Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 55 : 49-55, 2008.
P.225 掲載の参考文献
1) Lloyd RV, et al (ed) : WHO Classification of Tumours of Endocrine Organs, 4th ed (World Health Organization Classification of Tumours), IARC Press, Lyons, 2017.
2) 一般社団法人日本内分泌学会「悪性褐色細胞腫の実態調査と診療指針の作成」委員会 (編) : 褐色細胞腫・パラガングリオーマ診療ガイドライン 2018, 日本内分泌学会雑誌 94 (Suppl. August), 2018.
4) 成瀬光栄, ほか : 厚生労働科学研究費補助金難治性疾患克服研究事業「褐色細胞腫の実態調査と診療指針の作成」研究班, 平成22年度報告書, 2011.
P.231 掲載の参考文献
1) Manger WM, Gifford RW Jr : Pheochromocytoma : a clinical overview. In : Hypertension : Pathophysiology, Diagnosis, and Management, 2nd ed, Vol 2 (ed by Laragh JH, et al), p2225-2244, Raven Press, New York, 1995.
2) 成瀬光栄, ほか : 褐色細胞腫・パラガングリオーマ診療ガイドライン 2018 全国疫学調査. 日本内分泌学会雑誌 94 (Suppl Aug) : 4-7, 2018.
8) Amar L, et al : Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23 : 8812-8818, 2005.
10) 竹越一博, 櫻井晃洋 : 遺伝性褐色細胞腫・パラガングリオーマ症候群の遺伝子解析. 褐色細胞腫診療マニュアル [改訂第2版] (成瀬光栄, 平田結喜緒編), p70-77, 診断と治療社, 2012.
11) 日本医学会ホームページ, 日本医学会ガイドライン. [http://jams.med.or.jp/guideline/genetics-diagnosis.html] (2018年10月閲覧)
P.236 掲載の参考文献
1) 和中明生, ほか : 末梢神経系神経節ニューロンの発生. 人体発生学 (遠山正彌, ほか編), p369-376, 南山堂, 2003.
2) 成瀬光栄, ほか : 厚生労働科学研究費補助金難治性疾患克服研究事業「褐色細胞腫の実態調査と診療指針の作成」研究班, 平成21年度研究報告書, 2010.
4) Stenstrom G, Svardsudd K : Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220 : 225-232, 1986.
5) Greene Jp, Guay AT : New perspectives in pheochromocytoma. Urol Clin North Am 16 : 487-503, 1989.
6) Hume DM : Pheochromocytoma in the adult and in the child. Am J Surg 99 : 458-496, 1960.
7) Daneman A : Adrenal neoplasms in children. Semin Roentgenol 23 : 205-215, 1988.
8) Gimenez-Roqueplo AP, et al : Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63 : 5615-5621, 2003.
11) Burnichon N, et al : The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94 : 2817-2827, 2009.
12) Amar L, et al : Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23 : 8812-8818, 2005.
13) Pasini B, et al : SDH mutations in tumorigenesis and inherited endocrine tumours : lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266 : 19-42, 2009.
15) Pacak K, et al : Diagnostic localization of pheochromocytoma : the coming of age of positron emission tomography. Ann N Y Acad Sci 970 : 170-176, 2002.
P.241 掲載の参考文献
1) WHO Classification of Tumours of Endocrine Organs, 4th ed (ed by Lloyd RV, et al), WHO Classification of Tumours, Volume 10, IARC, Lyon, 2017.
2) 成瀬光栄 : 厚生労働省難治性疾患克服研究事業「褐色細胞腫の実態調査と診療指針の作成」研究班, 平成21年度研究報告書, 2010.
4) Kimura N, et al : Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis : a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16 : 23-32, 2005.
6) Mishra AK, et al : Catecholamine cardiomyopathy in bilateral malignant pheochromocytoma : successful reversal after surgery. Int J Cardiol 76 : 89-90, 2000.
P.244 掲載の参考文献
1) Lloyd RV, et al (ed) : WHO Classification of Tumours of Endocrine Organs, 4th ed, p183-189, p248-252, International Agency for Research on Cancer, Lyon, 2017.
2) 日本泌尿器科学会, 日本病理学会 (編) : 泌尿器科・病理 副腎腫瘍取扱い規約, p52-53, 金原出版, 1992.
5) 日本泌尿器科学会, ほか (編) : 副腎腫瘍取扱い規約 (第3版), p94-100, 金原出版, 2015.
6) Romanet P, et al : Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocr Pathol 28 : 302-307, 2017.
7) 飯島宗一, ほか : 現代病理学大系 (第17巻B), p291-292, 中山書店, 1991.
8) Rudy FR, et al : Adrenal medullary hyperplasia : aclinicopathologic study of four cases. Hum Pathol 11 : 650-657, 1980.
9) 多発性内分泌腫瘍症情報サイト MEN診断の手引き, p12, 2012. [http://men-net.org/medical/guidance.html] (2018年10月閲覧)
10) Modigliani E, et al : Pheochromocytoma in multiple endocrine neoplasia type 2 : European study. The Euromen Study Group. J Intern Med 238 : 363-367, 1995.
P.248 掲載の参考文献
1) Lam KY, Lo CY : Adrenal lipomatous tumours : a 30 year clinicopathological experience at a single institution. J Clin Pathol 54 : 707-712, 2001.
4) 柳瀬敏彦 : 副腎偶発腫瘍の鑑別診断と治療. 日本内科学会雑誌 103 : 650-656, 2014.
5) Mantero F, et al : A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85 : 637-644, 2000.
6) Kasperlik-Zeluska AA, et al : Incidentally discovered adrenal mass (incidentaloma) : investigation and management of 208 patients. Clin Endocrinol (Oxf) 46 : 29-37, 1997.
7) Singla AK, et al : Giant presacral myelolipoma. Am Surg 69 : 334-338, 2003.
8) Hagiwara H, et al : Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency. Endocr Pathol 19 : 122-127, 2008.
9) Caliumi C, et al : A rare combination consisting of aldosterone-producing adenoma and adrenal myelolipoma in a patient with heterozygosity for retinoblastoma (RB) gene. J Renin Angiotensin Aldosterone Syst 5 : 45-48, 2004.
10) Maschler I, et al : Ectopic functioning adrenocortico-myelolipoma in longstanding Nelson's syndrome. Clin Endocrinol (Oxf) 10 : 493-497, 1979.
12) Inuzuka M, et al : A case of myelolipoma with bilateral adrenal hyperaldosteronism cured after unilateral adrenalectomy. Intern Med 51 : 479-485, 2012.
15) Russell C, et al : Spontaneous rupture of adrenal myelolipoma : spiral CT appearance. Abdom Imaging 25 : 431-434, 2000.
P.252 掲載の参考文献
1) 乾あやの : Wolman病 ; 造血器腫瘍と類縁疾患. 組織球増殖性疾患. リピドーシス. 別冊日本臨牀 新領域別症候群シリーズ No.23 血液症候群 (第2版) III, p500-503, 日本臨牀社, 2013.
2) 村上潤, 福嶋健志 : ライソゾーム酸性リパーゼ欠損症-Wolman病, CESD. 医学のあゆみ 264 : 829-832, 2018.
4) Ikari N, et al : Lysosomal Acid Lipase Deficiency in Japan : A Case Report of Siblings and a Literature Review of Cases in Japan. J Nippon Med Sch 85 : 131-137, 2018.
6) Bernstein DL, et al : Cholesteryl ester storage disease : review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol 58 : 1230-1243, 2013.
8) Hamilton J, et al : Anew method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 413 : 1207-1210, 2012.
P.255 掲載の参考文献
1) Hammond GL et al : Primary structure of human corticosteroid binding globulin, deduced from hepatic and pulmonary cDNAs, exhibits homology with serine protease inhibitors. Proc Natl Acad Sci USA 84 : 5153-5157, 1987.
6) Ho JT, et al : Septic shock and sepsis : a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab 91 : 105-114, 2006.
12) Brunner E, et al : Hereditary corticosteroid-binding globulin deficiency due to a missense mutation (Asp367Asn, CBG Lyon) in a Brazilian kindred. Clin Endocrinol (Oxf) 58 : 756-762, 2003.
13) Van Baelen H, et al : Transcortin Leuven : a variant of human corticosteroid-binding globulin with decreased cortisol-binding affinity. J Biol Chem 257 : 3397-3400, 1982.
16) Torpy DJ, et al : Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. Endocr Res 30 : 417-429, 2004.
P.260 掲載の参考文献
1) Moore KL, Persaud TVN : The Developing Human : Clinically Oriented Embryology, 6th ed, p339-340, WB Saunders, St. Louis, 1998.
2) 笹野公伸 : 副腎皮質の発生異常. 別冊日本臨牀 領域別症候群シリーズ 内分泌症候群 (上巻), p545-547, 日本臨牀社, 1993.
3) Lin L, Achermann J : Inherited adrenal hypoplasia : not just for kids! Clin Endocrinol (Oxf) 60 : 529-537, 2004.
5) Bennett J, et al : IMAGe Syndrome. GeneReviews(R) [Internet], 2014, Mar. 13. [updated 2016, Sep. 8]
6) Narumi S, et al : SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 48 : 792-797, 2016.
8) Gondo S, et al : SF-1/Ad4BP transforms primary long-term cultured bone marrow cells into ACTH-responsive steroidogenic cells. Genes Cells 9 : 1239-1247, 2004.
9) 柳瀬俊彦 : 副腎の発生分化と再生. 医学のあゆみ 213 : 397-400, 2005.
IV 副甲状腺・骨・ミネラル代謝
P.267 掲載の参考文献
1) Silverberg SJ, Bilezikian JP : Primary hyperparathyroidism. In : Endocrinology, 5th ed., vol. 2 (ed by DeGroot LJ, Jameson JL), p1533-1554, Elsevier, Philadelphia, 2005.
2) Press DM, et al : The prevalence of undiagnosed and unrecognized primary hyperparathyroidism : a population-based analysis from the electronic medical record. Surgery 154 : 1232-1237 ; discussion 1237-1238, 2013.
3) Imanishi Y, et al : Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin DI in transgenic mice. J Clin Invest 107 : 1093-1102, 2001.
6) Imanishi Y, et al : Pathogenesis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. In : Hemodialysis (ed by Suzuki H), p81-100, InTech, Rijeka, 2013.
8) Vestergaard P, et al : Parathyroid surgery is associated with a decreased risk of hip and upper arm fractures in primary hyperparathyroidism : a controlled cohort study. J Intern Med 255 : 108-114, 2004.
9) Khan AA, et al : Alendronate in primary hyperparathyroidism : a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89 : 3319-3325, 2004.
10) Kawata T, et al : Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24 : 300-306, 2006.
P.273 掲載の参考文献
P.276 掲載の参考文献
1) Giusti F, et al : Multiple Endocrine Neoplasia Type 1. In : GeneReviews [Internet] (ed by Adam MP, et al), University of Washington, Seattle, 1993.
2) 多発性内分泌腫瘍症診療ガイドブック編集委員会 (編) : 多発性内分泌腫瘍症診断ガイドブック, 金原出版, 2013.
3) Warner J, et al : Genetic testing in familial isolated hyperparathyroidism : unexpected results and their implications. J Med Genet 41 : 155-160, 2004.
7) Nesbit MA, et al : Mutations affecting G-protein subunit al1 in hypercalcemia and hypocalcemia. N Engl J Med 368 : 2476-2486, 2013.
10) 内野眞也, ほか : MEN以外の家族性副甲状腺機能亢進症. 日本内分泌・甲状腺外科学会雑誌 32 : 179-183, 2015.
13) Prazeres HJ, et al : Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clin Endocrinol (Oxf) 64 : 659-666, 2006.
14) 竹内靖博, ほか (編) : 虎の門病院内分泌ハンドブック-外来・入院からフォローアップまで (改訂版), 医薬ジャーナル社, 2016.
P.280 掲載の参考文献
1) Alagaratnam S, Kurzawinski TR : Aetiology, Diagnosis and Surgical Treatment of Primary Hyperparathyroidism in Children : New Trends. Horm Res Paediatr 83 : 365-375, 2015.
3) Vahe C, et al : Diseases associated with calcium-sensing receptor. Orphanet J Rare Dis 12 : 19, 2017.
4) Koo WWK : Neonatal Calcium, Magnesium, and Phosphorus Disorders. In : Pediatric Endocrinology, 5th ed, vol 2 (ed by Lifshitz F), p497-529, Informa Healthcare USA, New York, 2007.
5) Root AW, Diamond FB : Disorders of mineral homeostasis in the newborn, infant, child, and adolescent, In : Pediatric Endocrinology, 3rd ed (ed by Sperling MA), p686-769, Saunders Elsevier, Philadelphia, 2008.
P.284 掲載の参考文献
1) Hyde SM, et al : CDC73-Related Disorders. In : Adam MP, et al, (eds). GeneReviews(R) [Internet]. Seattle (WA) : University of Washington, Seattle, 1993-2018. 2008 Dec 31. [updated 2018 Apr 26]
3) Jackson CE, et al : Hereditary hyperparathyroidism and multiple ossifying jaw fibromas : a clinically and genetically distinct syndrome. Surgery 108 : 1006-1012 ; discussion 1012-1013, 1990.
7) Tomson BN, Arndt KM : The many roles of the conserved eukaryotic Pafl complex in regulating transcription, histone modifications, and disease states. Biochim Biophys Acta 1829 : 116-126, 2013.
8) Van Oss SB, et al : Emerging Insights into the Roles of the Pafl Complex in Gene Regulation. Trends Biochem Sci 42 : 788-798, 2017.
11) DeLellis RA, et al : Heritable forms of primary hyperparathyroidism : acurrent perspective. Histopathology 72 : 117-132, 2018.
P.289 掲載の参考文献
3) DeLellis RA : Parathyroid carcinoma : an overview. Adv Anat Pathol 12 : 53-61, 2005.
6) Yamashita H, et al : Light and electron microscopic study of nonfunctioning parathyroid carcinoma. Report of a case with a review of the literature. Acta Pathol Jpn 34 : 123-132. 1984.
7) 飯原雅季, ほか : 副甲状腺癌の発生機序と診断と治療. 日本内分泌・甲状腺外科学会雑誌 29 : 201-205, 2012.
8) 小原孝男, 藤本吉秀 : 上皮小体癌. 内分泌外科 1 : 179-187, 1984.
9) Wang CA, Gaz RD : Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 149 : 522-527, 1985.
10) 小原孝男, ほか : 原発性上皮小体機能亢進症-上皮小体癌の診断と治療方針. 外科診療 29 : 171-177, 1987.
P.293 掲載の参考文献
1) 厚生労働省難治性疾患克服研究事業ホルモン受容機構異常に関する調査研究班 : ビタミンD不足・欠乏の判定指針. LI本内分泌学会雑誌 93 : 1-10, 2017.
2) 日本腎臓学会 (編) : CKD診療ガイド 2012, 東京医学社, 2012.
4) Imanishi Y, et al : Chapter 5 Pathogenesis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. In : Hemodialysis (ed by Suzuki H), 81-100, InTech, Rijeka, 2013.
6) Ketteler M, et al : Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update : what's changed and why it matters. Kidney Int 92 : 26-36, 2017.
8) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日本透析医学会雑誌 45 : 301-356, 2012.
9) Kawata T, et al : Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24 : 300-306. 2006.
P.299 掲載の参考文献
2) Underbjerg L, et al : The Epidemiology of Nonsurgical Hypoparathyroidism in Denmark : A Nationwide Case Finding Study. J Bone Miner Res 30 : 1738-1744, 2015.
3) Astor MC, et al : Epidemiology and Health-Related Quality of Life in Hypoparathyroidism in Norway. J Clin Endocrinol Metab 101 : 3045-3053, 2016.
5) Zlotgora J, Cohen T : Idiopathic hypoparathyroidism in Israel. Isr J Med Sci 17 : 53-54, 1981.
6) 尾形悦郎, ほか : 厚生省特定疾患ホルモン受容機構異常調査研究班, 昭和59年度総括研究事業報告書, 1985,
10) Baron J, et al : Mutations in the Ca (2+) -sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 5 : 601-606, 1996.
P.305 掲載の参考文献
4) Ertl DA, et al : A novel homozygous mutation in the parathyroid hormone gene (PTH) in a girl with isolated hypoparathyroidism. Bone 51 : 629-632, 2012.
6) Lee S, et al : A Homozygous [Cys25] PTH (1-84) Mutation That Impairs PTH/PTHrP Receptor Activation Defines a Novel Form of Hypoparathyroidism. J Bone Miner Res 30 : 1803-1813, 2015.
7) Ray K, et al : Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca2+ receptor critical for dimerization. Implications for function of monomeric Ca2+ receptor. J Biol Chem 274 : 27642-27650, 1999.
10) Nesbit MA, et al : Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N Engl J Med 368 : 2476-2486, 2013.
12) Piret SE, et al : Identification of a G-Protein Subunit-α11 Gain-of-Function Mutation, Val340Met, in a Family With Autosomal Dominant Hypocalcemia Type 2 (ADH2). J Bone Miner Res 31 : 1207-1214, 2016.
13) Bowl MR, et al : Identification and characterization of novel parathyroid-specific transcription factor Glial Cells Missing Homolog B (GCMB) mutations in eight families with autosomal recessive hypoparathyroidism. Hum Mol Genet 19 : 2028-2038, 2010.
16) Li D, et al : Heterozygous Mutations in TBX1 as a Cause of lsolated Hypoparathyroidism. J Clin Endocrinol Metab, 2018. [Epub ahead of print]
P.308 掲載の参考文献
1) DiGeorge AM : Discussion on a new concept of the cellular basis of immunology. J Pediatr 67 : 907-908, 1965.
2) de la Chapelle A, et al : A deletion in chromosome 22 can cause DiGeorge syndrome. Hum Genet 57 : 253-256, 1981.
3) Kelley RI, et al : The association of the DiGeorge anomalad with partial monosomy of chromosome 22. J Pediatr 101 : 197-200, 1982.
4) Burn J, et al : Conotruncal anomaly face syndrome is associated with a deletion within chromosome 22q11. J Med Genet 30 : 822-824, 1993.
5) Shprintzen RJ, et al : The velo-cardio-facial syndrome : a clinical and genetic analysis. Pediatrics 67 : 167-172, 1981.
6) Wilson DI, et al : DiGeorge syndrome with isolated aortic coarctation and isolated ventricular septal defect in three sibs with a 22q11 deletion of maternal origin. Br Heart J 66 : 308-312, 1991.
7) McDonald-McGinn DM, et al : 22q11.2 deletion syndrome. Nat Rev Dis Primers 1 : 15071, 2015.
10) 大久保直, 高田慎治 : 咽頭弓からの胸腺形成と先天性異常の発症機構. 生化学 84 : 168-176, 2012.
11) 小児慢性特定疾病情報センター. [https://www.shouman.jp/disease/instructions/10_02_019/] (2018年10月閲覧)
12) Rezaeil N, et al (ed) : Primary Immunodeficiency Diseases, Springer-Verlag, Berlin, Heidelberg 2008.
13) European Society for Immunodeficiencies : DiGeorge Syndrome diagnostic criteria (Clinical Working Party). [http://esid.org/Working-Parties/Clinical/Resources/Diagnostic-criteria-for-PID2#Q50] (2018年10月閲覧)
P.313 掲載の参考文献
2) Finnish-German APECED Consortium : An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 17 : 399-403, 1997.
4) 松本穣, ほか : Aire遺伝子と自己免疫性多内分泌腺症候群1型. 最新医学 73 : 688-692, 2018.
9) Orlova EM, et al : Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type l. J Clin Endocrinol Metab 102 : 3546-3556, 2017.
15) Guo CJ, et al : The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev 17 : 78-85, 2018.
P.317 掲載の参考文献
2) Abboud B, et al : Risk factors for postthyroidectomy hypocalcemia. J Am Coll Surg 195 : 456-461, 2002.
3) Kakava K, et al : Postsurgical Hypoparathyroidism : A Systematic Review. In Vivo 30 : 171-179, 2016.
6) Edafe O, et al : Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 101 : 307-320, 2014.
8) Yamashita H, et al : Postoperative tetany in Graves disease : important role of vitamin D metabolites. Ann Surg 229 : 237-245. 1999.
9) Witteveen JE, et al : Hungry bone syndrome : still a challenge in the post-operative management of primary hyperparathyroidism : a systematic review of the literature. Eur J Endocrinol 168 : R45-53, 2013.
10) Crea N et al : Predictive factors for postoperative severe hypocalcaemia after parathyroidectomy for primary hyperparathyroidism. Am Surg 78 : 352-358, 2012.
12) Quitterer U, et al : Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J Biol Chem 276 : 6763-6769, 2001.
15) Bollerslev J, et al : European Society of Endocrinology Clinical Guideline : Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173 : Gl-20, 2015.
P.321 掲載の参考文献
6) Bastepe M, et al : Pseudohypoparathyroidism. New insights into an old disease. Endocrinol Metab Clin North Am 29 : 569-589, 2000.
9) Turan S, et al : Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous Gas disruption. J Bone Miner Res 29 : 749-760, 2014.
13) Davies SJ, et al : Imprinting in Albright's hereditary osteodystrophy. J Med Genet 30 : 101-103, 1993,
P.326 掲載の参考文献
1) Haldeman-Englert CR, et al : Disorders of GIVAS inactivation. In : GeneReviews(R) [Internet] (ed by Adam MP, et al), University of Washington, Seattle, 1993-2018, 2017.
8) Huso DL, et al : Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy. PLoS ONE 6 : e21755, 2011.
11) Godinho RO, et al : New perspectives in signaling mediated by receptors coupled to stimulatory Gprotein : the emerging significance of cAMP efflux and extracellular cAMP-adenosine pathway. Front Pharmacol 6 : 58, 2015.
12) Lemos MC, et al : GNAS mutations in Pseudohypoparathyroidism type 1aand related disorders. Hum Mutat 36 : 11-19, 2015.
14) Yeh GL, et al : GNAS1 mutation and Cbfal misexpression in a child with severe congenital platelike osteoma cutis. J Bone Miner Res 15 : 2063-2073, 2000.
P.330 掲載の参考文献
1) Botto LD, et al : A population-based study of the 22q11.2 deletion : phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112 : 101-107, 2003.
2) Zhang X, et al : A modified multiplex ligation-dependent probe amplification method for the detection of 22q11.2 copy number variations in patients with congenital heart disease. BMC Genomics 16 : 364, 2015.
4) Singh SM, et al : Monozygotic twins with chromosome 22q11 deletion and discordant phenotypes : updates with an epigenetic hypothesis. J Med Genet 39 : e71, 2002.
6) McDonald-McGinn DM, et al : 22q11.2 deletion syndrome. Nat Rev Dis Primers 1 : 15071, 2015.
8) Kunishima S, et al : Bernard-Soulier syndrome caused by a hemizygous GPIbβmutation and 22q11.2 deletion. Pediatr Int 55 : 434-437, 2013.
10) Ammann AJ, et al : The DiGeorge syndrome and the fetal alcohol syndrome. Am J Dis Child 136 : 906-908, 1982.
11) Vermot J, et al : Decreased embryonic retinoic acid synthesis results in a DiGeorge syndrome phenotype in newborn mice. Proc Natl Acad Sci USA 100 : 1763-1768, 2003.
13) Greenhalgh KL, et al : 22q11 deletion : amultisystem disorder requiring multidisciplinary input. Arch Dis Child 88 : 523-524, 2003.
P.333 掲載の参考文献
6) Hernandez AM, et al : Novel mutation in the gene encoding the GATA3 transcription factor in a Spanish familial case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with female genital tract malformations. Am J Med Genet A 143A : 757-762, 2007.
7) Fukami M, et al : GATA3 abnormalities in six patients with HDR syndrome. Endocr J 58 : 117-121, 2011.
8) Nakamura A, et al : Molecular analysis of the GATA3 gene in five Japanese patients with HDR syndrome. Endocr J 58 : 123-130, 2011.
9) Matsuo K, et al : Novel splice site mutation in GATA3 in a patient with HDR syndrome. Clin Pediatr Endocrinol 26 : 271-273, 2017.
10) Muroya K, et al : GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. J Med Genet 38 : 374-380, 2001.
11) Lichtner P, et al : An HDR (hypoparathyroidism, deafness, renal dysplasia) syndrome locus maps distal to the DiGeorge syndrome region on 10p13/14. J Med Genet 37 : 33-37, 2000.
13) 鈴木完, ほか : 尿路感染に伴う敗血症性ショックを契機に診断されたHDR (hypoparathyroidism-deafness-renal dysplasia) 症候群の1例. 日本小児泌尿器科学会雑誌 24 : 52-55, 2015.
P.339 掲載の参考文献
1) Kenny FM, Linarelli L : Dwarfism and cortical thickening of tubular bones. Transient hypocalcelnia in a mother and son. Am J Dis Child 111 : 201-207, 1966.
2) Caffey Jp : Congenital stenosis of medullary spaces in tubular bones and calvaria in two proportionate dwarfs-mother and son ; coupled with transitory hypocalcemic tetany. Am J Roentgenol Radium Ther Nucl Med 100 : 1-11, 1967.
3) 磯島豪, 北中幸子 : Kenny-Caffey症候群と類縁疾患. 日本臨牀 73 : 1959-1964, 2015,
8) Courtens W, et al : Hypoparathyroidism-retardation-dysmorphism syndrome in a girl : A new variant not caused by a TBCE mutation-clinical report and review. Am J Med Genet A 140 : 611-617, 2006.
11) Larsen JL, et al : Unusual cause of short stature. Am J Med 78 : 1025-1032, 1985.
12) Parvari R, et al : Parathyroid development and the role of tubulin chaperone E. Horm Res 67 : 12-21, 2007.
13) Hoffman WH, et al : Kenny-Caffey syndrome and microorchidism. Am J Med Genet 80 : 107-111, 1998.
P.346 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会 (委員長 : 折茂肇) 編 : 骨粗鬆症の予防と治療ガイドライン 2015年版, ライフサイエンス出版, 2015.
4) Whittier X, Saag KG : Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am 42 : 177-189, x, 2016.
5) Wolf RL, et al : Update on the epidemiology of osteoporosis. Curr Rheumatol Rep 2 : 74-86, 2000.
P.352 掲載の参考文献
2) Oka R, et al : Fracture risk assessment tool (FRAX) and for the diagnosis of osteoporosis in Japanese middle-aged and elderly women : Chiba bone survey. Endocr J 65 : 193-202, 2018.
4) 茶木修 : 閉経期～老年期における骨量減少および骨粗鬆症. 産科と婦人科 79 : 1489-1495, 2012.
5) Tatsuno I, et al : Lifestyle and osteoporosis in middle-aged and elderly women : Chiba bone survey. Endocr J 60 : 643-650, 2013.
13) Jackson RD, et al : Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy : results from the women' s health initiative randomized trial. J Bone Miner Res 21 : 817-828, 2006.
P.358 掲載の参考文献
1) 大中佳三, 高柳涼一 : ステロイド骨粗鬆症の予防と治療. 医学のあゆみ 221 : 113-118, 2007.
3) Caplan A, et al : Prevention and management of glucocorticoid-induced side effects : A comprehensive review : A review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol 76 : 1-9, 2017.
7) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines, Arthritis Rheum 39 : 1791-1801, 1996.
9) Sato AY, et al : Protection From Glucocorticoid-lnduced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. J Bone Miner Res 31 : 1791-1802, 2016.
15) Kalpakcioglu BB, et al : Advanced imaging assessment of bone fragility in glucocorticoidinduced osteoporosis. Bone 48 : 1221-1231, 2011.
16) Graeff C, et al : High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 52 : 568-577, 2013.
18) Buckley L, et al : 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-lnduced Osteoporosis. Arthritis Rheumatol 69 : 1521-1537, 2017.
P.362 掲載の参考文献
1) 日本骨代謝学会, ほか (編) : 原発性骨粗鬆症の診断基準 (2012年度改訂版). Osteoporosis Japan 21 : 9-21, 2013.
2) Ebeling PR : Clinical practice. Osteoporosis in men. N Engl J Med 358 : 1474-1482, 2008.
6) Drake MT, et al : Clinical review. Risk factors for low bone mass-related fractures in men : a systematic review and meta-analysis. J Clin Endocrinol Metab 97 : 1861-1870, 2012.
7) Khosla S, et al : Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86 : 3555-3561, 2001.
8) LeBlanc ES, et al : The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 94 : 3337-3346, 2009.
11) 骨粗髭症の予防と治療ガイドライン作成委員会 (編) : 骨粗髭症の予防と治療ガイドライン 2015年版, ライフサイエンス出版, 2015.
12) Ebeling PR : Osteoporosis in men. Cur Opin Rheumatol 25 : 542-552, 2013.
13) Greenspan SL, et al : Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : a randomized trial. Ann Intern Med 146 : 416-424, 2007.
16) 日本泌尿器科学会 (編) : 前立腺癌診療ガイドライン 2012年版, 金原出版, 2012.
P.367 掲載の参考文献
2) Fukumoto S, et al : Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. Endocr J 62 : 665-671, 2015.
6) Walton RJ, Bijvoet OL : Nomogram for derivation of renal threshold phosphate concentration. Lancet 2 : 309-310, 1975.
7) Okazaki R, et al : Assessment criteria for vitamin D deficiency/insufficiency in Japan-proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J 64 : 1-6, 2017.
8) Carpenter TO, et al : A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26 : 1381-1388, 2011.
10) Carpenter TO, et al : Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124 : 1587-1597, 2014.
P.371 掲載の参考文献
6) Folpe AL, et al : Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity : an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28 : 1-30, 2004,
7) Lee JC, et al : Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29 : 1335-1346, 2016.
8) Fukumoto S, et al : Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab 33 : 467-473, 2015.
10) Jan de Beur SM, et al : Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359 : 761-763, 2002.
14) Fukumoto S : Targeting fibroblast growth factor 23 signaling with antibodies and inhibitors. Is there a rationale? Front Endocrinol (Lausanne) 9 : 48, 2018.
P.375 掲載の参考文献
2) Fukumoto S, et al : Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society. Endocr J 62 : 665-671, 2015.
4) Fan HC, et al : The lmpact of Anti-Epileptic Drugs on Growth and Bone Metabolism. Int J Mol Sci 17. pii : E1242, 2016.
6) Agene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11 : 130-136, 1995.
14) Okazaki R, et al : Assessment criteria for vitamin D deficiency/insufficiency in Japan : proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. J Bone Miner Metab 35 : 1-5, 2017.
P.381 掲載の参考文献
7) Michigami T, et al : Common mutations F310 L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. Eur J Pediatr 164 : 277-282, 2005.
8) Mochizuki H, et al : Severe hypercalcaemia and respiratory insufficiency associated with infantile hypophosphatasia caused by two novel mutations of the tissue-nonspecific alkaline phosphatase gene. Eur J Pediatr 159 : 375-379, 2000.
10) Tadokoro M, et al : New bone formation by allogeneic mesenchymal stem cell transplantation in apatient with perinatal hypophosphatasia. J Pediatr 154 : 924-930, 2009.
P.387 掲載の参考文献
3) Gunther W, et al : The ClC-5 chloride channel knock-out mouse-an animal model for Dent's disease. Pflugers Arch 445 : 456-462, 2003.
8) Shrimpton AE, et al : OCRL1 mutations in Dent 2 patients suggest a mechanism for phenotypic variability. Nephron Physiol 112 : 27-36, 2009.
9) Sekine T, et al : Japanese Dent disease has a wider clinical spectrum than Dent disease in Europe/USA : genetic and clinical studies of 86 unrelated patients with low-molecular-weight proteinuria. Nephrol Dial Transplant 29 : 376-384, 2014.
12) Piwon N, et al : ClC-5 Cl- -channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408 : 369-373, 2000.
13) 島友子 : Dent病・Lowe症候群. 小児腎臓病学 [改訂第2版] (日本小児腎臓病学会編), p251-254, 診断と治療社, 2017.
P.390 掲載の参考文献
1) Prader A, et al : [An unusual form of primary vitamin D-resistant rickets with hypocalcemia and autosomal-dominant hereditary transmission : hereditary pseudo-deficiency rickets. (Article in German)] Helv Paediatr Acta 16 : 452-468, 1961.
9) Hewison M, et al : Tissue resistance to 1,25-dihydroxyvitamin D without a mutation of the vitamin D receptor gene. Clin Endocrinol (Oxf) 39 : 663-670, 1993.
P.394 掲載の参考文献
1) Bianchine JW, et al : Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7 : 287-295, 1971.
6) Imel EA, et al : Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone 60 : 87-92, 2014.
13) Riedler GF, Scheitlin WA : Hypophosphataemia in septicaemia : higher incidence in gram-negative than in gram-positive infections. Br Med J 1 : 753-756, 1969.
15) Kumar A, et al : Iron replacement as a therapeutic approach for renal phosphate wasting with associated iron deficiency. AACE Clin Case Rep 3 : e260-263, 2017.
P.398 掲載の参考文献
1) Markby DW, et al : Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 262 : 1895-1901, 1993.
2) Gejman PV, et al : Genetic mapping of the Gs-alpha subunit gene (GNAS1) to the distal long arm of chromosome 20 using a polymorphism detected by denaturing gradient gel electrophoresis. Genomics 9 : 782-783, 1991.
5) Schmidt H, Kiess W : Secondary central precocious puberty in a girl with McCune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab 11 : 77-81, 1998.
7) Swislocki AL, et al : McCune-Albright syndrome. A case of primary hypogonadism obscured by hyperprolactinemic hypogonadotropic hypogonadism. West J Med 153 : 653-656, 1990.
10) Riminucci M, et al : Osteoclastogenesis in fibrous dysplasia of bone : in situ and in vitro analysis of IL-6 expression. Bone 33 : 434-442, 2003.
13) Majoor BC, et al : Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. J Bone Miner Res 33 : 84-90, 2018.
14) 山本威久, ほか : 乳腺の乳管内乳頭腺腫を合併したMcCune-Albright症候群の1例. ホルモンと臨床 52 : 149-152, 2004.
P.402 掲載の参考文献
1) Witteveen JE, et al : Hungry bone syndrome : still a challenge in the post-operative management of primary hyperparathyroidism : a systematic review of the literature. Eur J Endocrinol 168 : R45-53, 2013.
2) Natsui K, et al : Oxyphil parathyroid adenoma associated with primary hyperparathyroidism and marked post-operative hungry bone syndrome. Intern Med 35 : 545-549, 1996.
5) Edafe O, et al : Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 101 : 307-320, 2014.
P.406 掲載の参考文献
5) 小崎慶介, ほか : 2015年版骨系統疾患国際分類の和訳. 日本整形外科学会雑誌 91 : 462-505, 2017.
8) 田中弘之, ほか : 骨形成不全症の診療ガイドライン. 日本小児科学会雑誌 110 : 1468-1471, 2006.
9) Cho TJ, et al : Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop 25 : 607-612, 2005.
11) Bishop N, et al : A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25 : 32-40, 2010.
P.411 掲載の参考文献
1) Paget J : On a Form of Chronic Inflammation of Bones (Osteitis Deformans). Med Chir Trans 60 : 37-649, 1877.
2) Maldague B, et al : Dynamic radiologic patterns of Paget's disease of bone. Clin Orthop Relat Res (217) : 126-151, 1987.
3) Barker DJp, et al : Paget's disease of bone : the Lancashire focus. Br Med J 280 : 1105-1107, 1980.
4) Hashimoto J, et al : Prevalence and clinical features of Paget's disease of bone in Japan. J Bone Miner Metab 24 : 186-190, 2006.
6) Luxton RW : Paget's disease of bone associated with Hashimoto's struma lymphomatosa ; a clue to the pathogenesis of Paget's disease? Lancet 272 : 441-443, 1957.
8) Layfield R, Hocking LJ : SQSTM1 and Paget's disease of bone. Calcif Tissue Int 75 : 347-357, 2004.
10) Middleton-Hardie C, et al : Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. J Bone Miner Res 21 : 438-445, 2006.
12) Alexandersen P, et al : Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20 : 588-595, 2005.
13) Meunier PJ, et al : Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum 23 : 1095-1103, 1980.
15) Yoh K, et al : Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone. J Bone Miner Metab 28 : 468-476, 2010.
P.416 掲載の参考文献
7) Tominaga Y, et al : Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13 : 78-86, 1997.
10) 日本透析医学会 : 慢性腎臓病に伴う骨・ミネラル代謝. 異常の診療ガイドライン. 日本透析医学会雑誌 45 : 301-356, 2012.
P.420 掲載の参考文献
6) Cabral CE, et al : Polyostotic fibrous dysplasia associated with intramuscular myxomas : Mazabraud's syndrome. Skeletal Radiol 27 : 278-282, 1998.
10) Jackson CE, et al : Hereditary hyperparathyroidism and multiple ossifying jaw fibromas : a clinically and genetically distinct syndrome. Surgery 108 : 1006-1012 ; discussion 1012-1013, 1990.
11) Hayashi K, et al : Diagnosis and treatment of low-grade osteosarcoma : experience with nine cases. Int J Clin Oncol 19 : 731-738, 2014.
P.424 掲載の参考文献
10) Cleiren E, et al : Albers-Sch6nberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10 : 2861-2867, 2001.
12) Palagano E, et al : Hematopoietic stem cell transplantation corrects osteopetrosis in a child carrying a novel homozygous mutation in the FERMT3 gene. Bone 97 : 126-129, 2017.
P.428 掲載の参考文献
2) Broadus AE, Nissenson RA : Parathyroid hormone-related protein. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed (ed by Favus MJ), p99-106, American Society for Bone and Mineral Research, Washington DC, 2006.
4) Tanaka Y, et al : Calcium dependency of the production of interleukin 1 and the expression of interleukin 1 receptors of human adult T-cell leukemia cells in vitro. Cancer Res 50 : 4344-4348, 1990.
5) Gurney H, et al : Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 341 : 1611-1613, 1993.
6) LeGrand SB, et al : Narrative review : furog. emide for hypercalcemia : an unproven yet common practice. Ann Intern Med 149 : 259-263, 2008.
7) Major P, et al : Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy : apooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 : 558-567, 2001.
8) Terpos E, et al : The use of bisphosphonates in multiple myeloma : recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20 : 1303-1317, 2009.
P.433 掲載の参考文献
1) Kondo S, et al : The safety and effectiveness profile of eldecalcitol in a prospective, postmarketing observational study in Japanese male patients with osteoporosis. J Bone Miner Metab, 2018. [Epub ahead of print]
2) Bhalia K, et al : Hypercalcemia caused by iatrogenic hypervitaminosis A. J Am Diet Assoc 105 : 119-121, 2005.
3) Okazaki R, et al : Assessment criteria for vitamin D deficiency/insufficiency in Japan-proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J 64 : 1-6, 2017.
4) Belanger LF, Clark I : Alpharadiographic and histological observations on the skeletal effects of hypervitaminoses A and D in the rat. Anat Rec 158 : 443-451, 1967.
6) McPherson ML, et al : Theophylline-induced hypercalcemia. Ann Intern Med 105 : 52-54, 1986.
8) Albert U, et al : Effects of maintenance lithium treatment on serum parathyroid hormone and calcium levels : a retrospective longitudinal naturalistic study. Neuropsychiatr Dis Treat 11 : 1785-1791, 2015.
9) Legha SS, et al : Tamoxifen-induced hypercalcemia in breast cancer. Cancer 47 : 2803-2806, 1981.
10) Kuroi K, et al : Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer : a case report. J Med Case Rep 5 : 495, 2011.
11) Zerwekh JE, et al : The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res 13 : 1594-1601, 1998.
P.438 掲載の参考文献
2) Carroll MF, Schade DS : Apractical approach to hypercalcemia. Am Fam Physician 67 : 1959-1966, 2003.
3) 古川洋太郎 : 高カルシウム血性クリーゼ. 日本臨牀 45 (増刊 : 広範囲症候群) : 694, 1987.
4) 三木隆己, 中弘志 : Ca代謝に関する検査 (1). 骨・カルシウム検査ハンドブック (森井浩世編), p10-18, 中山書店, 1996.
5) Payne RB, et al : Interpretation of serum total calcium : effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32 : 56-60, 1979.
6) 鈴木尚直 : 高カルシウム血症. 虎の門病院内分泌ハンドブック (竹内靖博, ほか編), p234-239, 医薬ジャーナル社, 2012.
7) 竹内靖博 : I. 高カルシウム血症 1. 鑑別診断. 日本内科学会雑誌 96 : 656-661, 2007.
8) LeGrand SB, et al : Narrative review : furosemide for hypercalcemia : an unproven yet common practice. Ann Intern Med 149 : 259-263, 2008.
9) Seymour JF, Gagel RF : Calcitriol : the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 82 : 1383-1394, 1993.
P.442 掲載の参考文献
5) Hannan FM, et al : Identification of 70 calcium-sensing receptor mutations in hyper-and hypocalcaemic patients : evidence for clustering of extracellular domain mutations at calciumbinding sites. Hum Mol Genet 21 : 2768-2778, 2012.
8) Nesbit MA, et al : Mutations affecting G-protein subunit alphall in hypercalcemia and hypocalcemia. N Engl J Med 368 : 2476-2486, 2013.
10) Pallais JC, et al : Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J Clin Endocrinol Metab 96 : 672-680, 2011.
11) Loupy A, et al : PTH-independent regulation of blood calcium concentration by the calciumsensing receptor. J Clin Invest 122 : 3355-3367, 2012.
12) Makita N, Iiri T : Biased agonism : a novel paradigm in G protein-coupled receptor signaling observed in acquired hypocalciuric hypercalcemia. Endocr J 61 : 303-309, 2014.
14) Bertocchio JP, et al : Pro-FHH : A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia. J Clin Endocrinol Metab 103 : 2534-2542, 2018.
15) Mayr B, et al : GENETICS IN ENDOCRINOLOGY : Gain and loss of function mutations of the calcium-sensing receptor and associated proteins : current treatrnent concepts. Eur J Endocrinol 174 : R189-208, 2016.
P.446 掲載の参考文献
2) British Paediatric Association : Hypercalcaemia in infants and vitamin D. Br Med J 2 : 149, 1956.
5) Meusburger E et al : Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcaemia and a novel CYP24A1 mutation. Clin Kidney J 6 : 211-215, 2013.
7) Wolf P, et al : A Case of "Late-Onset" Idiopathic Infantile Hypercalcemia Secondary to Mutations in the CYP24A1 Gene. Endocr Pract 20 : e91-95, 2014.
P.450 掲載の参考文献
1) Cope CL : Base changes in alkalosis produced by the treatment of gastric ulcers with alkalies. Clin Sci 2 : 297-300, 1936.
2) Jamieson MJ : Hypercalcaemia. Br Med J (Clin Res Ed) 290 : 378-382, 1985.
3) Beall DP, et al : Milk-alkali syndrome : ahistorical review and description of the modern version of the syndrome. Am J Med Sci 331 : 233-242, 2006.
12) Punsar S, Somer T : The milk-alkali syndrome. A report of three illustrative cases and a review of the literature. Acta Med Scand 173 : 435-449, 1963.
P.458 掲載の参考文献
1) Ward LM, et al : Disorders of calcium, phosphate, and bone metabolism. In : Pediatric Endocrinology and Inborn Errors of Metabolism, 2nd ed (ed by Sarafoglou K, et al), p799-874, McGraw Hill, New York, 2017.
2) 新生児医療連絡会 (編) : 低カルシウム血症. NICUマニュアル (第5版), p369-372, 金原出版, 2014.
3) 難波範行 : 新生児期の低カルシウム血症. 小児科学レクチャー 3 : 1086-1094, 2013.
4) Carpenter TO : Disorders of Mineral Metabolism in Childhood. In : Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th ed (ed by Rosen CJ), p651-658, John Wiley & Sons, Hoboken, 2013.
5) Jassam N, et al : Calcium adjustment equations in neonates and children. Ann Clin Biochem 49 (Pt 4) : 352-358, 2012,
6) Tsang RC, et al : Possible pathogenetic factors in neonatal hypocalcemia of prematurity. The role of gestation, hyperphosphatemia, hypomagnesemia, urinary calcium loss, and parathor-mone responsiveness. J Pediatr 82 : 423-429, 1973.
7) Venkataraman PS, et al : Early neonatal hypocalcemia in extremely preterm infants. High incidence, early onset, and refractoriness to supraphysiologic doses of calcitriol. Am J Dis Child 140 : 1004-1008, 1986.
13) 難波範行 : 低カルシウム血症. 内分泌代謝科専門医研修ガイドブック (日本内分泌学会編), p105-108, 診断と治療社, 2018.
14) Rustico SE, et al : Metabolic bone disease of prematurity. J Clin Transl Endocrinol 1 : 85-91, 2014.
P.461 掲載の参考文献
2) 日本内分泌学会 : 低カルシウム血症の鑑別診断の手引き. [https://square.umin.ac.jp/endocrine/tebiki/003/003001.pdf] (2018年10月閲覧)
3) Bringhurst FR, et al : Hypocalcemic disorders. In : Williams Textbook of Endocrinology, 10th ed (ed by Larsen PR, et al), p1340-1348, Saunders, Philadelphia, 2003.
P.465 掲載の参考文献
1) Macefield G, Burke D : Paraesthesiae and tetany induced by voluntary hyperventilation. Increased excitability of human cutaneous and motor axons. Brain 114 (Pt 1B) : 527-540, 1991.
2) Tohme JF, Bilezikian Jp : Hypocalcemic emergencies. Endocrinol Metab Clin North Am 22 : 363-375, 1993.
3) Cohen L : Potassium replacement associated with the development of tetany in a patient with hypomagnesaemia. Magnes Res 6 : 43-45, 1993.
4) Jacob J, et al : Tetany induced by hypokalemia in the absence of alkalosis. Am J Med Sci 291 : 284-285, 1986.
5) Flink EB : Magnesium deficiency. Etiology and clinical spectrum. Acta Med Scand Suppl 647 : 125-137, 1981.
7) Jesus JE, Lardry A : Images in clinical medicine. Chvostek's and Trousseau's signs. N Engl J Med 367 : e15, 2012.
8) 鈴木二郎, 大塚文男 : 副甲状腺機能低下症 ; 第4章 副甲状腺疾患と骨代謝異常. 医学スーパーラーニングシリーズ 内分泌・糖尿病内科学 (森昌朋編), p124-128, シュプリンガー・ジャパン, 2011.
9) 稲福徹也 : テタニーの診かた. medicina 55 : 1404-1407, 2018.
10) 竹内靖博 : カルシウム代謝疾患の救急 ; 高カルシウム血症クリーゼと低カルシウム血症性テタニー. 日本内科学会雑誌 105 : 658-666, 2016.
11) 山内美香, 杉本利嗣 : 内分泌疾患 : 診断と治療の進歩 IV. 副甲状腺-Ca検査値異常のアプローチ. 日本内科学会雑誌 103 : 870-877, 2014.
12) 日本呼吸器学会 : 過換気症候群. [http://www.jrs.or.jp/modules/citizen/index.php?content_id=41] (2018年8月閲覧)
P.470 掲載の参考文献
9) Harvey JN, et al : Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf) 37 : 97-103, 1992.
11) Wilson FH, et al : A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science 306 : 1190-1194, 2004.
P.474 掲載の参考文献
4) Ing SW, Pelliteri PK : Diagnostic fine-needle aspiration biopsy of an intrathyroidal parathyroid gland and subsequent eucalcemia in a patient with primary hyperparathyroidism. Endocr Pract 14 : 80-86, 2008.
5) Pontikides N, et al : Diagnostic and therapeutic review of cystic parathyroid lesions. Hormones (Athens) 11 : 410-418, 2012.
7) Akel M, et al : Successful treatment of parathyroid cyst using ethanol sclerotherapy. Am J Med Sci 317 : 50-52, 1999.
8) Dell' Amore A, et al : Thoracoscopic resection of a giant mediastinal parathyroid cyst. Gen Thorac Cardiovasc Surg 62 : 444-450, 2014.
P.480 掲載の参考文献
1) 冨永芳博 : 副甲状腺の歴史. 副甲状腺機能亢進症の外科 (冨永芳博編), p6-9, 東京医学社, 2016.
2) Sadler TW : 頭・頸部. ラングマン人体発生学 (第6版) (Sadler TW編), p269-296, 医歯薬出版, 1991.
3) 佐藤伸也, ほか : 甲状腺内副甲状腺腫10例の検討-術前の局在診断について-. 頭頸部外科 24 : 207-216, 2014.
4) Yabuta T, et al : Ultrasonographic features of intrathyroidal parathyroid adenoma causing primary hyperparathyroidism. Endocr J 58 : 989-994, 2011.
5) 政次俊宏, ほか : 異所性副甲状腺腫による原発性副甲状腺機能亢進症19例の検討. 日本臨床外科学会雑誌 63 : 2353-2357, 2002.
6) Proye C, et al : [Hyperparathyroidism and intrathyroid parathyroid gland. 43 cases]. Ann Chir 48 : 501-506, 1994.
8) Miyauchi A, et al : Piriform sinus fistula. A route of infection in acute suppurative thyroiditis. Arch Surg 116 : 66-69, 1981.
11) 岡本高宏 : 原発性副甲状腺機能亢進症 手術治療. 副甲状腺・骨代謝疾患診療マニュアル (竹内靖博, ほか編), p57-59, 診断と治療社, 2013.
12) Obara T, et al : Mid-mediastinal parathyroid lesions : preoperative localization and surgical approach in two cases. Jpn J Surg 20 : 481-486, 1990.
13) 佐藤伸也ほか : 胸腔鏡下に摘出した動脈管索近傍の縦隔内副甲状腺腫の1例. 日本臨床外科学会雑誌 74 : 2389-2393, 2013.
14) 松岡慎, ほか : 手術後のさまざまな二次性副甲状腺機能亢進症 副甲状腺の数と位置異常. 副甲状腺機能亢進症の外科 (冨永芳博編), p113-121, 東京医学社, 2016.
最近チェックした商品履歴
Loading...
販売価格 14,025 円（税込）
III 副腎
-
III 副腎P.3
-
1. 副腎皮質機能低下症P.5
-
(1) 先天性副腎低形成症P.5
-
(2) 慢性副腎皮質機能低下症 ( 原発性, 続発性 )P.9
IV 副甲状腺・骨・ミネラル代謝
-
IV 副甲状腺・骨・ミネラル代謝P.261
-
1. 副甲状腺機能亢進症P.263
-
(1) 原発性副甲状腺機能亢進症P.263
-
(2) 無症候性副甲状腺機能亢進症P.268